Cancer Center Amsterdam
-
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
Lameris, R., Ruben, J. M., Iglesias-Guimarais, V., de Jong, M., Veth, M., van de Bovenkamp, F. S., de Weerdt, I., Kater, A. P., Zweegman, S., Horbach, S., Riedl, T., Winograd, B., Roovers, R. C., Adang, A. E. P., de Gruijl, T. D., Parren, P. W. H. I. & van der Vliet, H. J., 21 Mar 2023, In: Cell Reports Medicine. 4, 3, p. 100961 100961.Research output: Contribution to journal › Article › Academic › peer-review
-
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Saura-Esteller, J., de Jong, M., King, L. A., Ensing, E., Winograd, B., de Gruijl, T. D., Parren, P. W. H. I. & van der Vliet, H. J., 16 Jun 2022, In: Frontiers in immunology. 13, 915837.Research output: Contribution to journal › Review article › Academic › peer-review
- All publications